School Access to Naloxone Act of 2026
Summary
S3588 authorizes a grant program for schools to stock naloxone but contains no mandated procurement or direct spending; the committees have held a single hearing. The bill is at an early procedural stage with no appropriation attached and no guaranteed revenue impact for any company. Naloxone manufacturers (JNJ) could see negligible upside if states later appropriate funds, but the legislative risk is low because the financial stakes are near zero.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S3588 authorizes a school-naloxone grant program but does not appropriate any funds; no revenue is committed.
- 2.Naloxone manufacturers (JNJ, generic producers) could see minuscule incremental sales only if appropriators later provide funding — unlikely in an election year.
- 3.Bicameral companion (HR9251) and related Overdose RADAR Act show broader opioid-crisis attention, but legislatively immature (one hearing in 6 months).
- 4.The bill has zero hard enforcement or procurement mandates: 'may award grants' — no obligation for any party to buy anything.
Market Implications
No market-moving implications from this bill alone. Naloxone manufacturers JNJ and ABBV (the two largest pharma tickers in the provided data) derive negligible revenue from emergency naloxone. The broader opioid-crisis legislative environment (RADAR Act, state opioid settlements) could sustain general healthcare-sector interest, but the specific financial signal from S3588 is zero.
Full Analysis
The School Access to Naloxone Act of 2026 (S3588) was introduced in the Senate on January 7, 2026, by Sen. Merkley (D-OR) with six bipartisan cosponsors. The bill amends the Public Health Service Act to create a new grant program (Sec. 544A) that would allow school personnel who undergo training to administer naloxone or similar drugs/devices in the event of a suspected opioid overdose. The Committee on Health, Education, Labor, and Pensions held hearings on March 19, 2026 — the only action since referral.
The bill authorizes grant-making but does NOT specify any dollar amounts (the funding amendment in Sec. 2(b) merely strikes and inserts language about the authorization section, with no hard ceilings). Because this is an authorization-only vehicle, actual school-purchase dollars require a separate appropriation from the Labor-HHS-Education appropriations bill. The financial mechanism is entirely permissive: eligible entities may apply for grants, but no funds are directed. An identical companion bill (HR9251) has been introduced in the House and referred to the Energy and Commerce Committee, which increases the likelihood of eventual bicameral convergence but does not move the funding needle.
Related bills strengthen the legislative narrative: the Overdose RADAR Act (S690) is a data-surveillance bill that complements the Naloxone Act by improving overdose-incident tracking — together they represent a bipartisan push to improve the federal opioid response infrastructure, but neither carries direct procurement obligations. The RADAR Act is in committee and has not moved since referral.
Structural winners: For-profit naloxone manufacturers include JNJ (Narcan) and Emergent BioSolutions (generic naloxone) — however, the bill does not name either company or any particular product. The dominant market position of Narcan (JNJ) and existing generic competition means any sales from this program would flow to whichever distributor schools choose, at low volume and low margin. Emergent BioSolutions is not publicly traded in the provided data; Teva, Mylan (now part of Viatris), and others also produce generic naloxone. The revenue impact for any single company is far below 1% of revenue.
Timeline: The bill has cleared only one committee stage — a hearing. Next steps: full committee markup, then Senate floor vote, then House passage (HR9251 must proceed through Energy and Commerce), then conference if differences exist, then final passage, then appropriation. Given the 119th Congress is in its second session (2026), the remaining window for enactment narrows as the 2026 midterm elections approach. The most likely outcome is no passage this session, or a narrow authorizing bill that gets rolled into a larger health package — still without material revenue for any company.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Grant program authorizing the administration of naloxone (an opioid overdose reversal drug) in schools; JNJ manufactures and sells naloxone products (brand Narcan) through its Janssen subsidiary, but the bill does not mandate a specific product or procurement channel.
Who must act
Eligible entities (school districts and their personnel) that choose to apply for grants under section 544A of the Public Health Service Act.
What happens
The bill authorizes (but does not appropriate) grants for schools to purchase and maintain supplies of naloxone and administration devices. No federal procurement volumes are set; market demand depends on state/local decisions and eventual appropriations.
Stock impact
JNJ's Narcan franchise could see incremental unit sales from school purchases if grants are funded, but the per-unit revenue is small (list price ~$75/dose) relative to JNJ's $85.2B total revenue; a hypothetical 100,000-dose annual purchase would be <0.01% of revenue.
What the bill does
Same grant program but through ABBV's naloxone product positioning — ABBV does not have a branded naloxone product; its portfolio includes the addiction-treatment drug Suboxone (buprenorphine/naloxone), but the bill funds emergency reversal, not treatment, so Suboxone is not directly covered.
Who must act
Eligible entities (school districts). Drug acquisition decisions by schools are unregulated; no mandate for ABBV products.
What happens
ABBV's Suboxone is an opioid use disorder maintenance therapy, not an emergency reversal drug. Schools administering narcotic-reversal drugs use naloxone-only products (Narcan, generic), not buprenorphine combinations. The bill has essentially zero revenue implication for ABBV.
Stock impact
No mechanical link: ABBV derives ~$54.3B revenue from immunology, oncology, and aesthetics — addiction is a tiny segment. The school-naloxone program does not support ABBV's product lines.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
HELP Copays Act
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Centers for Medicare & Medicaid Services of the Department of Health and Human Services relating to "Medicare Program; Implementation of Prior Authorization for Select Services for the Wasteful and Inappropriate Services Reduction (WISeR) Model".
Biosimilar Red Tape Elimination Act
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
A bill to amend the Public Health Service Act to streamline the review of biosimilar biological products.
A bill to require the Secretary of Health and Human Services to conduct a national, evidence-based education campaign to increase public and health care provider awareness regarding the potential risks and benefits of human cell and tissue products transplants, and for other purposes.
To amend the Federal Food, Drug, and Cosmetic Act to establish special rules to provide for continued review of human drug and device submissions during a lapse of appropriations, and for other purposes.
A bill to prohibit certain uses of automated decision systems by employers, and for other purposes.
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security
President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).
Advancing Regenerative Agriculture and Strengthening American Farm Resilience
This executive order directs the EPA, USDA, and HHS to prioritize registration of alternative pesticides, expedite cumulative exposure research, and maximize funding for a regenerative agriculture pilot program, while creating public-private partnerships to expand adoption of conservation farming practices. The order specifically instructs the EPA Administrator to speed up registration actions for substances that can replace older active ingredients, and requires HHS to issue a grand prize challenge for cumulative chemical exposure evaluation technologies.
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →